13 11 20

Information and support

  • Get informed
  • Get support
  • Cut my risk
  • Get involved
  • Research
  • CVPM087A2101

    Acronym: 

    CVPM087A2101

    ACTRN/NCT /ethics: 

    NCT03798626

    Scientific title: 

    Gevokizumab With Standard of Care Anti-cancer Therapies for Metastatic Colorectal, Gastroesophageal, and Renal Cancers

    Summary of trial and patient characteristics

    Cancer Type Bowel and colon, Kidney, Stomach & Oesophageal
    Trial Type Treatment
    Phase Phase I Tumour Stream Colorectal and gastroesophageal cancerRenal cell carcinoma
    Age Range 18 years and older Cancer Stage Metastatic or Widespread
    Sex Both Anticipated Start Date
    Molecular Target Anticipated End Date
    Cancer Type Bowel and colon, Kidney, Stomach & Oesophageal
    Trial Type Treatment
    Phase Phase I
    Age Range 18 years and older
    Sex Both
    Molecular Target
    Tumour Stream Colorectal and gastroesophageal cancerRenal cell carcinoma
    Cancer Stage Metastatic or Widespread
    Anticipated Start Date
    Anticipated End Date

    Trial Summary

    This study will determine the pharmacodynamically-active dose of gevokizumab and the tolerable dose and preliminary efficacy of gevokizumab in combination with the standard of care anti-cancer therapy in patients with metastatic colorectal cancer, metastatic gastroesophageal cancer and metastatic renal cell carcinoma.

    Lay Summary

    Gevokizumab With Standard of Care Anti-cancer Therapies for Metastatic Colorectal, Gastroesophageal, and Renal Cancers

    Sponsor / Cooperative group

    Novartis Pharmaceuticals

    Participating Hospitals

    Hospital Clinical Trial Coordinator Email Phone Principal Investigator Recruitment Status
    The Queen Elizabeth Hospital Pamela Cooper pamela.cooper@sa.gov.au 08 8222 6410 Professor Tim Price Recruiting